07:00 , Oct 27, 2016 |  BC Innovations  |  Translation in Brief

Blueprint for fusion

Blueprint Medicines Corp. (NASDAQ:BPMC) and researchers at The Rockefeller University are ramping up their collaboration to develop inhibitors of a disease-driving fusion protein found in all patients with fibrolamellar carcinoma, a rare subtype of hepatocellular...
07:00 , Jun 26, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Adrenocortical adenoma Protein kinase cAMP-dependent catalytic-a (PRKACA) DNA sequencing of patient samples and in vitro studies suggest inhibiting PRKACA could treat adrenocortical carcinoma. DNA sequencing...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Cushing's disease Protein kinase cAMP-dependent catalytic-a (PRKACA) L205R Genetic sequencing studies identified an activating PRKACA mutation in Cushing's disease that could help model the disorder....
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer DnaJ (Hsp40) homolog subfamily B member 1 (DNAJB1); protein kinase cAMP-dependent catalytic-a (PRKACA) Human sample and in vitro studies suggest inhibiting the DNAJB1-PRKACA...
08:00 , Nov 13, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuropathy Protein kinase, cAMP-dependent, catalytic, a (PRKACA; PKACA); protein kinase, X-linked (PRKX); patatin-like phospholipase domain containing 6 (PNPLA6; NTE) Studies in...